**Activity** | 2021 Pennsylvania Chapter Emerging Fields of Cardiology Series - Amyloids - FACULTY

**Workflow Status:** NeedsReview

## Required Types

### Personal Commercial (8)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self</td>
<td>Self</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam Pharma</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Noninvasive Imaging</td>
</tr>
<tr>
<td>Astellas Pharma US</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Noninvasive Imaging</td>
</tr>
<tr>
<td>Astellas Pharma US</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Noninvasive Imaging</td>
</tr>
<tr>
<td>Ionis Pharma</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Other</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Research/Research Grants</td>
<td>Significant (&gt;= $5,000)</td>
<td>Heart Failure and Cardiomyopathies</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Consultant Fees/Honoraria</td>
<td>Modest (&lt; $5,000)</td>
<td></td>
</tr>
</tbody>
</table>

† Commercial Funding Source | ‡ Trial Name

## Required Agreements

- **Education Attestation Agreement** | Signed on 7/14/2021
  
  URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

- **Confidentiality, Disclosure and Assignment Agreement** | Signed on 7/14/2021
  
  URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

- **Embargo Agreement for Published Content and LBCTs** | Signed on 7/14/2021
  
  URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

- **Annual Statement and On-Going Obligation Agreement** | Signed on 7/14/2021
  
  URL for full agreement: [http://disclosures.acc.org/Public/Definition/AnnualStatementandOnGoingObligationAgreement](http://disclosures.acc.org/Public/Definition/AnnualStatementandOnGoingObligationAgreement)

## Reviewer History

- Prem Soman, MD, PhD, FACC

Printed as of 7/15/2021
ACC and Disclosures
ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.